Особенности применения торасемида при артериальной гипертензии
Аннотация
Об авторах
Г. А. БарышниковаРоссия
С. А. Чорбинская
Россия
Список литературы
1. Шальнова С.А., Деев А.Д., Баланова Ю.А. и др. Динамика артериальной гипертонии в России: есть ли прогресс в назначении антигипертензивной терапии? Результаты исследований 1993-2013 гг. Сердце. 2015; 6: 2145.
2. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска развития сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54 (10): 4-12.
3. Диагностика и лечение артериальной гипертензии. Российские рекомендации, IV пересмотр. Системные гипертензии. 2010; 7 (3): 5-26.
4. Рекомендации по диагностике и лечению артериальной гипертонии ESH и ESC. Евразийский кардиологический журн. 2014; 1: 7-76
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
6. Lindholm L.H, Hansson L. Sweedish trial in old patients with hypertension 2 (STOP-Hypertension 2). Blood Press 1996; 5: 300-4.
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (The antihypertensive and lipid lowering treatment to prevent heart attack trial - ALLHAT). JAMA 2002; 288: 2981-97.
8. Psaty B.M. Health outcomes associated with various antihypertensive therapies used as a first line agents. A Network meta-analysis. JAMA 2003; 289: 2534-44.
9. Wright J.M, Musini V.M. First-line drugs for hypertension. Cohrane Database Syst Rev 2009; 8 (3): CD001841.
10. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.
11. Sarafidis P, Barkis G.L. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes care 2006; 29: 1167-9.
12. Fernandez J.G, Rodriguez-Perez J.C, Garrido J. et al. Effect of two antihypertensive combinations on metabolic control in type-2 dibetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-56.
13. Friedel H, Buckley M. Torasemide A.review of its pharmacological properties and therapeutic potential. Drugs 1991; 41 (1): 81-103.
14. Brunner G, von Bergmann K, Hacker W. et al. Comparison of diuretic effects and pharmacokinetics of torasemid and furosemid after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzt-Forsch. Drug Res 1998; 38: 176-79.
15. Barr W.H, Smith H.L, Karnes H.A.T. et al. Torasemide dose-proportionality of pharmacokinetics and pharmacodynamics. In: Progress in Pharmacology and Clinical Pharmacology, Gustav-Fischer-Verlag Stuttgart, New York, 1990; 8 (1): 29-37.
16. Bolke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs Tod 1994; 30 (8): 1-28.
17. Reyes A. Effects of diuretics on outputs and flows or urine and urinary solutes in healthy subjects. Drugs 1991; 41 (Suppl. 3): 35-59.
18. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80-91.
19. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 169-81.
20. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63-8.
21. Liguori A, Casini A, Di Loreto M et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol 1999; 55: 117-24.
22. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190-3.
23. Reyes A.J, Chiesa P.D, Santucci M.R. et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 183-209.
24. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2.5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 211-20.
25. Mosso L, Carvajal C, Gonzalez A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.
26. Schunkert H, Hense H.W, Muscholl M. et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77: 24-31.
27. Tanabe A, Naruse M, Naruse K. et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997; 20 (2): 85-90.
28. Brown N.J. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14 (3): 235-41.
29. Young M.J, Lam E.Y, Rickard A.J. Mineralocorticoid receprtor activator and cardiac fibrosis. Clin Sci (Lond) 2007; 112 (9): 467-75.
30. Goodfriend T.L, Ball D.L, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45-50.
31. Franse L.V, Pahor M, Di Bari M. et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025-30.
32. Аверин Е.Е. Влияние торасемида на гипертрофию миокарда левого желудочка. Сердечная недостаточность. 2012; 13 (3): 158-61.
33. Massare J, Berry J.M, Luo X. et al. Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype. J Cardiovasc Electrophysiol 2010; 21 (9): 1031-7.
34. Шугушев Х.Х., Гаева А.А. Влияние фурасемида и торасемида на вариабельность сердечного ритма и желудочковые аритмии у больных с хронической сердечной недостаточностью, осложнившей течение ишемической болезни сердца: сравнительное нерандомизированное исследование. Рациональная фармакотерапия в кардиологии. 2010; 6 (4): 513-17.
35. Ткачева О.Н., Шарашкина Н.В., Новикова И.М. и др. Применение петлевого диуретика торасемида в комбинированном лечении гипертонической болезни у женщин в период постменопаузы. Consilium Medicum. 2011; 13 (10): 54-9.
36. Brown N.J. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14 (3): 235-41.
37. Born-Frontsberg E, Reincke M, Rump L.C. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94 (4): 1125-30.
38. Gonzaga C.C, Gaddam K.K, Ahmed M.I. et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6 (4): 363-68.
39. Yagi S, Akaike M, Aihara K. et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res 2011; 34 (1): 74-8.
40. Фомин В.В. Антиальдостероновое действие торасемида: случайность или необходимость? РМЖ. 2012; 14: 693-7.
41. Reyes A et al. In: Progress in Pharmacology and Clinical Pharmacology, Gustav-Fischer-Verlag Stuttgart, New York, 1992; 9: 219-62.
42. Liguori A, Casini A, Di Loreto M. et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol 1999; 55: 117-24.
43. Spieker C, Zidek W, Häcker W. et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38: 1188-90.
Рецензия
Для цитирования:
Барышникова Г.А., Чорбинская С.А. Особенности применения торасемида при артериальной гипертензии. Системные гипертензии. 2017;14(4):27-31.
For citation:
Baryshnikova G.A., Chorbinskajya S.A. Features of the use of torasemide in arterial hypertension. Systemic Hypertension. 2017;14(4):27-31.
Послать статью по эл. почте 